SymBio Pharmaceuticals closes Series E financing - MarketLine Financial Deals

SymBio Pharmaceuticals closes Series E financing

SymBio Pharmaceuticals closes Series E financing - MarketLine Financial Deals
SymBio Pharmaceuticals closes Series E financing
Published Feb 25, 2011
3 pages — Published Feb 25, 2011
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

SymBio Pharmaceuticals Limited, a Japan-based pharmaceutical company focused on oncology, hematology and autoimmune disease, has secured JPY2,000 million ($24.39 million) in Series E financing.

  
Source:
Document ID
MA52697_110302
Country
Country
Ticker
CEPH=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "SymBio Pharmaceuticals closes Series E financing" Feb 25, 2011. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/SymBio-Pharmaceuticals-closes-Series-E-financing-2052-56907>
  
APA:
MarketLine Financial Deals. (2011). SymBio Pharmaceuticals closes Series E financing Feb 25, 2011. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/SymBio-Pharmaceuticals-closes-Series-E-financing-2052-56907>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.